Rigel highlights initial data from ongoing phase 1b study evaluating r289 in lr-mds at the 66th ash annual meeting and exposition

R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated lr-mds patients rbc-ti/hi-e responses occurred in 40% of evaluable td patients receiving r289 doses ≥500 mg qd south san francisco, calif. , dec. 9, 2024 /prnewswire/ -- rigel pharmaceuticals, inc. (nasdaq: rigl), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial data from its ongoing phase 1b study evaluating r2891, an oral prodrug of r835, a potent and selective dual inhibitor of irak1 and irak4, in patients with relapsed or refractory (r/r) lower-risk myelodysplastic syndrome (lr-mds).
ASH Ratings Summary
ASH Quant Ranking